EXTH-44. DEVELOPMENT OF RETROVIRAL REPLICATING VECTORS ENCODING SEQUENCE-OPTIMIZED NITROREDUCTASE FOR PRODRUG ACTIVATOR GENE THERAPY IN HUMAN GLIOMA MODELS

Early-phase clinical trials of Toca 511, a retroviral replicating vector (RRV) expressing an optimized form of yeast cytosine deaminase for prodrug activator gene therapy, showed highly promising evidence of therapeutic benefit and increased survival in recurrent high-grade glioma, but an internatio...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Neuro Oncol
Päätekijät: Collins, Sara, Inagaki, Akihito, Tai, Chien-Kuo, Logg, Christopher R, Searle, Peter, Tangney, Mark, Kasahara, Noriyuki
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2020
Aiheet:
Preclinical Experimental Therapeutics
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651312/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.398
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia